JQ1 - Wikipedia
Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction | Nature Communications
Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | Moffitt
Next-generation epigenetic inhibitors
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Bromodomain inhibitors in clinical trials | Download Table
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer - ScienceDirect
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency - ScienceDirect
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression - ScienceDirect
Clinical trials of bromodomain and extra-terminal inhibitors. | Download Table
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
